key: cord-0891584-isbq1fqt
authors: D’Amico, Ferdinando; Baumgart, Daniel C.; Danese, Silvio; Peyrin-Biroulet, Laurent
title: Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management
date: 2020-04-08
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2020.04.001
sha: e7a4159ce5cead74ff87dc1199e3f461631adf96
doc_id: 891584
cord_uid: isbq1fqt

Abstract Background and aims The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 / COVID-19) pandemic is a worldwide emergency. An increasing number of diarrhea cases is reported. Here we investigate the epidemiology, clinical presentation, molecular mechanisms, management, and prevention of SARS-CoV-2 associated diarrhea. Methods We searched on PubMed, EMBASE, and Web of Science up to March 2020 to identify studies documenting diarrhea and mechansism of intestinal inflammation in patients with confirmed diagnosis of SARS-CoV-2 infection. Results Clinical studies show an incidence rate of diarrhea ranging from 2% to 50% of cases. It may precede or trail respiratory symptoms. A pooled analysis revealed an overall percentage of diarrhea onset of 10.4%. SARS-CoV uses the the angiotensin-converting enzyme 2 (ACE2) and the serine protease TMPRSS2 for S protein priming. ACE2 and TMPRSS2 are not only expressed in lung, but also in the small intestinal epithelia. ACE2 is expressed furthermore in the upper esophagus, liver, and colon. SARS-CoV-2 binding affinity to ACE2 is significantly higher (10-20 times) compared with SARS-CoV. Several reports indicate viral RNA shedding in stool detectable longer time period than in nasopharyngeal swabs. Current treatment is supportive, but several options appear promising and are the subject of investigation. Conclusion Diarrhea is a frequent presenting symptom in patients infected with SARS-CoV-2. Increasing evidence indicates possible fecal oral transmission, indicating the need for a rapid and effective modification of the screening and diagnostic algorithms. The optimal methods to prevent, manage, and treat diarrhea in COVID-19 infected patients are subjects of intensive research.

In December 2019, an outbreak of pneumonia of unknown etiology in Wuhan, Hubei province, China led to the identification of a new betacoronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 . SARS-CoV-2 is the seventh identified coronavirus that is able to infect humans 2 . In addition to animal origin it shares up to 80% of the gene sequence with other members of coronavirus family, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) 2,3 . Our understanding of SARS human-to-human transmission is still evolving, but is currently believed to occur through air droplets, although fecal oral spread and airborne transmission may be other sources of transmission 4, 5 . In a short time, the highly contagious virus has caused a pandemic, destabilizing health systems, economies, and governments around the world 6 .

SARS-CoV-2 infection can be asymptomatic or be associated with the coronavirus disease 2019 , which has a spectrum of respiratory clinical manifestations ranging from fever, dry cough, and dyspnea to pneumonia, pulmonary oedema, acute respiratory distress syndrome (ARDS), and multiple organ failures, requiring hospitalization in intensive care unit (ICU) and leading to death in severe cases 7 . Less common symptoms include headache, haemoptysis, nausea, vomiting, and diarrhea 8 . Although initially found in a small percentage of cases, an increasing number of patients present with diarrhea 9 . Diarrhea is a frequent symptom in coronavirus infections; it was detected in up to 30% of patients with MERS-CoV and 10.6% of patients with SARS-CoV 10, 11 . The purpose of this review is to examine the literature on the epidemiology, clinical symptoms, mechanism of action, management, and prevention of COVID 2019 associated diarrhea in order to better characterize this symptom and to identify any preventive measures for patients exposed to virus.

We searched PubMed, EMBASE, and Web of Science up to March 2020 in order to identify all studies documenting the presence of diarrhea in patients with confirmed diagnosis of COVID-19.

The following search terms alone or matched with the Boolean operators "AND" or "OR" were used: "COVID-19", "SARS-CoV-2", "coronavirus", "pandemic", "epidemic", "outbreak", "diarrhea", "gastrointestinal symptom", "stool", "feces". No temporal, study design, or language restrictions were applied. We focused on full-text articles, but abstracts were considered if relevant.

Additional studies were identified through the accurate evaluation of the reference list of the included works.

Coronaviruses are a family of single-stranded enveloped RNA viruses and their genome have a number of open reading frames (ORFs) ranging from six to eleven 12 . The first ORF contains most of the viral genome and encodes 16 non-structural proteins, while the other ORFs encode structural and accessory proteins 13, 14 . The remaining viral genome is responsible for the expression of 4 essential structural proteins, including spike glycoprotein, small envelope protein, matrix protein, and nucleocapsid protein 13, 14 . The SARS-CoV entry into a host cell is mediated by the interaction between the envelope-anchored viral spike protein and the host receptor, consisting of angiotensinconverting enzyme 2 (ACE2) 13 . Genomic characterization of SARS-CoV-2 showed a high homology degree between SARS-CoV-2 and SARS-CoV as regards the receptor-binding domain structure, indicating that the new virus could bind ACE2 and infect humans (Figure 1 ) 3 . The spike protein is functionally made up of two subunits, S1 and S2 13 . SARS-2-S uses ACE2 for entry 15 . The former mediates virus attachment to the host cell membrane, while the latter favors the fusion of the two cell membranes 16 . This process requires priming by cellular serine proteases (TMPRSS2), which allow spike protein cleavage, regulating the entire mechanism 16 . The virus infectivity mainly depends on binding affinity with ACE2 receptor 17 . Structural studies 17 showed that the new SARS-CoV-2 not only binds ACE2, but its binding affinity for human ACE2 is significantly stronger (10-20 times more) 18 than its 2003 SARS-CoV predecessor. A bioinformatics analysis 19 based on single-cell transcriptomes revealed that ACE2 was expressed in lung AT2 cells, upper esophagus, and in absorptive enterocytes from ileum and colon. Moreover, other studies provided additional evidence that coronaviruses may infect the gastrointestinal tract, since a high co-expression of ACE2 and TMPRSS2 was detected in enterocytes, as well as in the esophagus and lungs 4, 16 .

Although the specific mechanisms involved in diarrhea pathogenesis are not entirely known, viral infection is likely to cause an alteration of intestinal permeability, resulting in enterocyte malabsorption 4 . In addition, it has been proposed that intestinal ACE2 is involved in the uptake of dietary amino acids, regulating the expression of antimicrobial peptides and promoting the homeostasis of the gut microbiome 21 . Mouse models showed that the presence of ACE2 alterations was associated with colitis, suggesting that virus activity may cause enzyme modifications, increasing the susceptibility to intestinal inflammation and diarrhea 21 . Further studies are needed to clarify the mechanisms underlying diarrhea in these viral infections and to define the correlation between respiratory and gastrointestinal symptoms 22 .

Epidemiological data of COVID-19 patients with diarrhea are summarized in Table 1 . The medical records of the National Health Commission of China allowed to evaluate the data of 1099 Chinese patients with an established diagnosis of COVID-19 up to 31 January 2020 23 . Forty-two subjects experienced diarrhea (3.8%) and the primary composite outcome (admission to ICU, use of mechanical ventilation, or death) occurred in 4 patients with diarrhea (6%) 23 . In a retrospective study by Xu et al. 24 diarrhea occurred in 3/62 patients (4.8%). A symptom duration-based analysis showed that diarrhea was experienced only in patients who had symptoms for more than 10 days (3/33, 9%), while those who had a shorter duration had no diarrhea 24 . In a cross-sectional, Chinese multicenter study 9 enrolling 204 patients until early March 2020, diarrhea occurred in 29 cases (29.3%). The time between symptom onset and admission to the hospital was significantly longer in patients with digestive symptoms than in patients without gastrointestinal manifestations (9 vs. 7.3 days, p=0.02) 9 . Most patients had non-dehydrating loose stools and had an average of 3 evacuations per day 9 . No cases of severe diarrhea were detected, although a clinical relationship was reported between diarrhea and worsening of COVID-19 symptoms 9 . Wu et al. investigated a cluster of subjects exposed to the infection at the same time, documenting the presence of diarrhea in 15% of positive patients 25 . In the experience of Huang et al. 26 , only one out of 41 (3%) patients had diarrhea as initial symptom, while another Chinese study conducted in the Zhejiang province 8 reported a low rate of diarrhea onset in COVID-19 patients (2%). A study by Xiao et al. 27 analyzed stool samples from 73 COVID-19 patients to assess the clinical significance of measuring SARS-CoV-2 RNA in the feces. Diarrhea was found in 26 patients and the fecal test remained positive until 12 days after the disease onset 27 . It is worth mentioning that in 17 patients (23.3%) the stool test was still positive despite negative respiratory tests 27 . In addition, in a 78-year-old patient with severe respiratory distress treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO), endoscopic procedures were performed following signs of bleeding (coffee ground material from the nasogastric tube and positive fecal occult blood test) 27 . No mucosal damage was identified, but multiple esophageal, gastric, duodenal, and rectal biopsies were performed 27 . Histological analysis revealed a high percentage of ACE2 protein in the glandular cells of all examined segments, with the exception of the esophagus (mainly characterized by squamous cells), supporting the theory of a possible effect of the virus on these organs 27 . An 81-year-old Japanese woman with COVID-19 had watery diarrhea and the virus was detected in the stool for up to 15 days after disease onset 28 . In a descriptive case series 29 of the first 18 COVID-19 cases in Singapore, 3 patients had diarrhea (16.6%). None of these 3 patients had complications and none required supplemental oxygen 29 .

Stool samples were tested by real-time reverse transcriptase -polymerase chain reaction (RT-PCR) and SARS-CoV-2 was found in 4/8 patients (50%) from day 1 to day 7 29 . In a small case series 30 , data from 5 patients tested positive for both SARS-CoV-2 and influenza virus were analyzed, reporting diarrhea in 2 cases (40%). An analysis on the clinical characteristics of 30 medical members (22 doctors and 8 nurses) with COVID-19 showed the presence of diarrhea in 9/30 subjects (30%) 31 . Recently, the first study specifically designed to evaluate patients with gastrointestinal symptoms at disease onset was published 32 . One hundred eighty-three patients were included, and diarrhea was detected in 68 cases (37.1%). COVID-19 epidemiological data in children are lacking, however in a recent analysis 33 

Jin et al. 35 States also showed diarrheal symptoms for two consecutive days 37 . A stool sample was collected following loose bowel movements to verify the presence of the virus 37 . Importantly, the test was positive 7 days after the presumed onset of the disease, showing a high viral load 37 . Unfortunately, in the remaining studies diarrhea was not well characterized and no data were available regarding the total number of evacuations, consistency of the stools (Bristol scale), and duration of symptoms.

A symptom analysis based on COVID-19 severity (according to the American Thoracic Society guidelines for community-acquired pneumonia) showed a greater diarrhea percentage in patients with severe disease compared to those with non-severe disease (5.8% vs 3.5% respectively), suggesting an association between presence of symptom and disease severity 23 . Likewise, COVID-19 patients with diarrhea, nausea, and vomiting were more likely to require mechanical ventilation and had ARDS compared to patients without gastrointestinal symptoms (6.76% vs 2.08%, p=0.034, and 6.76% vs 2.08%, p=0.034, respectively) 35 . On the other hand, a case series of 138 patients found that diarrhea was present in 14 patients (10.1%) at disease onset and it was not associated with greater need for ICU care 7 . Another study compared the characteristics of COVID-19 patients who were underwent regular hospital management with patients who had more severe disease requiring mechanical ventilation or intensive care; the purpose of this analysi was to identify factors associated with poor prognosis in COVID-19. 38 . Among the 155 included patients, diarrhea occurred in 5 patients with severe disease and in 2 cases in the standard management group 38 .

Although this finding suggested a worse prognosis in patients with diarrhea, no correlation was found 38 . Additional studies are needed to clarify the correlation between diarrhea and the outcomes of COVID-19 patients.

Intestinal involvement and diarrhea in association with respiratory symptoms are common features to the other members of the coronavirus family 13 Watery diarrhea, without blood or mucus, was a frequent symptom, occurring in 28/138 patients (20.3%) at disease presentation 39 (Table 2 ). In 8 patients (5.8%) diarrhea was combined with fever, while 25 additional patients experienced diarrhea in the following 3 weeks, accounting for a total of 53 patients (38.4%) 39 . Mean duration of diarrhea was 3.7 days and evacuations ranged from few stools to 30 per day 39 . Patients with diarrhea had a higher need for ventilatory support (26.4% vs.

8.2%; p = 0.004) and intensive care (49.0% vs. 11.8%; p < 0.001), suggesting a greater disease severity, although no correlation with the mortality rate was found 39 . SARS-CoV was also identified in terminal ileal and colonic biopsies and RT-PCR fecal samples, where it was detectable up to 10 weeks after the onset of symptoms 39 . Data from Toronto SARS patients confirmed the incidence rates of diarrhea, which was reported in 23.6% of the infected patients 40 . However, inanother study by Peiris et al. 41 diarrhea was present in 1% of patients at onset, but 73% of infected people developed watery diarrhea after about one week. In regards to MERS, a descriptive study showed the presence of diarrhea in 12 cases (26%) 42 . In a study 43 on 186 MERS patients, diarrhea occurred in 26 subjects (14%). However, analyzing the data based on survival, a greater number of subjects who survived had diarrheal symptoms compared to the deceased (76.5% vs 46.4%, p = 0.05), indicating a less severe disease and a better prognosis in patients with diarrhea 43 . Another study 44 compared the clinical characteristics of medical staff and patients with MERS, and found a higher percentage of diarrheal symptoms in the former than in the latter (11 cases, 50% vs 5 cases, 23%, p value non-significant).

So far, no vaccines have been developed to prevent COVID-19, but several potential vaccines are being tested (NCT04299724, NCT04276896, NCT04313127, and NCT04283461). The current precautions adopted to contain the infection are standard measures for respiratory viral pathologies, including the use of masks and gloves, frequent hand hygiene (alcohol-based disinfectants or soap and water), travel restrictions, and avoiding contact with people suspected or confirmed to be infected 45 . The presence of virus in the stool and its long fecal persistence time suggest that orofecal transmission is possible, leading to several implications and requiring additional precautions.

First of all, contact with possible sources of contamination (e.g. saliva, vomiting, and feces) should be avoided with a greater attention to hygiene. 22 . Secondly, outpatient management should be modified. Deferable gastroenterologic consultations and non-urgent endoscopic procedures should be rescheduled and each patient should be stratified according to the symptoms or based on possible contact with infected people or origin from high-risk areas 46 . Personal protective equipment (PPE) including gloves, goggles, gowns, and respiratory protective devices should be adopted by healthcare professionals of the endoscopy units to avoid spreading the virus (Table 3) 46 . Thirdly, all candidates for fecal microbiota transplantation and healthy donors should be screened for the virus 47 . In addition, animal models showed that ACE and angiontensin receptor inhibition were associated with an increase in circulating ACE2 levels 48 . Based on diarrhea etiopathogenesis and on the key role of ACE2, the use of ACE or angiontensin receptor (AR) blockers should be investigated, particularly in elderly or cardiovascular patients, as it could lead to a higher risk of developing COVID-19 diarrhea 49 . Importantly, this hypothesis is not confirmed, and further investigations are needed to demonstrate whether the use of ACE/AR inhibitors is a risk factor for COVID-19.

Currently there is no specific treatment for COVID-19 and its management is mainly based on supportive care. No evidence on the efficacy of anti-diarrheal drugs is available, but an adequate rehydration and potassium monitoring should be performed as in all patients with diarrhea 50 . It is important to underline that antibiotics and antivirals are often used for COVID-19 treatment, involving a likely alteration of the gut microbiota and causing diarrhea 51, 52 . It is therefore plausible that the gut microbiota could be a new therapeutic target and that probiotics could have a role in the management of these patients 22, 53 . Interestingly, the China's National Health Commission recommended the use of probiotics for the treatment of patients with severe COVID-19 in order to preserve intestinal balance and to prevent secondary bacterial infections 22 . Moreover, a rapid improvement in diarrhea was also found after starting antiviral therapy 36 . Although no antiviral drug was specifically designed for the treatment of diarrhea, several molecules could have beneficial effects. Some monoclonal antibodies target the receptor-binding domain of the spike protein to inhibit the contact between the virus and ACE2 54 . Other attractive target is the TMPRSS2 protease, which plays a crucial role for viral infection 16 . Camostat mesylate a known effective inhibitor of TMPRSS2 and is already approved(in Japan for management of non-infectious conditions, such as chronic parncreatitis and reflux esophagitis; it is possible that this agent may work for COVID-19 20 .

A randomized, controlled, open-label trial evaluated the efficacy of lopinavir -ritonavir combination, two protease inhibitors, for the treatment of patients with confirmed diagnosis of COVID-19 55 . Unfortunately, no significant clinical improvement was found with this therapy 55 .

Remdesivir is a nucleotide analogue that prevents viral replication and that was effective (in combination with chloroquine) in blocking SARS-CoV-2 infection in vitro 56 . Chloroquine and hydroxychloroquine were used for the treatment of SARS and MERS and were effective in reducing coronavirus replication 57 . In in vitro studies, both drugs reduced SARS-CoV-2 replication, but hydroxychloroquine had greater inhibitory power than chloroquine 57 60 . It blocks both the AP2-associated protein kinase 1 (AAK1) and the cyclin G-associated kinase, which are two important regulators of cellular endocytosis, resulting in a theoretical reduction of the viral passage into the host cell 60 . The anti-inflammatory function and the anti-endocytic activity of baricitinib could be effective in diarrhea and deserve further studies 60 .

In the current SARS-CoV-2 pandemic, most of the attention is still exclusively focused on the respiratory symptoms of the disease. However, it is important to emphasize that the number of COVID-19 patients experiencing diarrhea is significant and cannot be overlooked. We found high variability among published studies in the percentage of patients with diarrhea, ranging from 2% to 50% of cases. Our pooled analysis of the available data revealed an overall diarrhea rate of about 10% in COVID-19 patients. This value is lower than the percentage of diarrhea reported with other coronaviruses 40,44 , but it is very possible that the available data may underestimate the burden of diarrhea associated with COVID-19 61 It was estimated that around 86% of the infections were not documented and that patients with undocumented cases led to the contagion of most of the identified patients (79%) 65 . SARS-CoV-2 is similar to SARS-CoV and MERS-CoV, but it is transmitted faster than its predecessors and for this reason a rapid and optimal diagnostic approach is essential to contain the virus dissemination 66 . The evidence of SARS-CoV-2 in the stools and in gastrointestinal histological samples and its prolongedpersistence at the stool compared to nasopharyngeal swabs strongly suggests that orofecal transmission is possible, justifying the execution of fecal PCR in suspect patients 27 . The homology between SARS-CoV-2 and SARS-CoV and MERS-CoV and the high capacity of these viruses to resist for long periods (even two weeks) at low temperatures and for a few days at temperatures between 20°C and 30 °C is a further confirmation of possible orofecal tranmission and requires an enhancement of preventive hygiene measures 67 .

In conclusion, the presence of diarrhea should generate suspicion of a possible SARS-CoV-2 infection and should be investigated in order to reach an early diagnosis of COVID-19. The incidence of diarrhea is currently underestimated and further studies are needed to quantify the exact burden of diarrhea to compare the sensitivity of fecal and nasopharyngeal tests, to evaluate whether diarrhea is a predictive factor for prognosis, and to clarify the effects of COVID-19 in patients with underlying gastrointestinal diseases. • Pay attention to hand hygiene before and after visiting a patient with diarrhea, using alcoholic disinfectants or soap and water.

• Patients with diarrhea should have a personal bathroom and bathroom sanitation should be performed several times per day • All endoscopes and reusable accessories should be reprocessed with standard reprocessing procedures

A Novel Coronavirus from Patients with Pneumonia in China

A new coronavirus associated with human respiratory disease in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Bat Coronaviruses in China

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

Origin and evolution of pathogenic coronaviruses

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation

Novel coronavirus infection and gastrointestinal tract

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Evidence for gastrointestinal infection of SARS-CoV-2

SARS-CoV-2 enterocolitis with persisting to excrete the virus for about two weeks after recovering from diarrhea: A case report

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China

Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia

Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19)

SARS-CoV-2 Infection in Children

novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19

First Case of 2019 Novel Coronavirus in the United States

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Enteric involvement of severe acute respiratory syndromeassociated coronavirus infection

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea

A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes

What Should Gastroenterologists and Patients Know About COVID-19?

COVID-19) outbreak: what the department of endoscopy should know

Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Oral therapy for acute diarrhea. The underused simple solution

Clinical practice. Antibiotic-associated diarrhea

HIV and diarrhoea: what is new?

Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection-A Systematic Literature Review

FDA-Approved Drugs

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus

Diarrhoeal disease

Using the big data ofinternet to understand coronavirus disease 2019's symptom characteristics: a big data study

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)

Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment